Literature DB >> 8909827

Drug interactions in patients infected with human immunodeficiency virus.

S C Piscitelli1, C Flexner, J R Minor, M A Polis, H Masur.   

Abstract

Patients with AIDS who are receiving optimal medical care, including combination therapy with antiretroviral agents and more effective prophylaxis and therapy for opportunistic infections and neoplasms, are surviving longer. However, the potential for drug interactions in these patients is increased because many of the currently used antibiotics and antiviral agents have profound effects on the hepatic cytochrome P-450 enzyme system, on renal tubular function, and on bone marrow function. In this AIDS Commentary, Dr. Piscitelli and colleagues have succinctly reviewed the current state of our knowledge regarding the potential for additive or synergistic drug interactions that can result in enhanced toxicity or, alternatively, augmented therapeutic benefit. Information on these interactions will become more important as more intensive and effective therapy becomes available for persons with far-advanced infection due to human immunodeficiency virus type 1.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8909827     DOI: 10.1093/clinids/23.4.685

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  23 in total

Review 1.  Antiretroviral-drug concentrations in semen: implications for sexual transmission of human immunodeficiency virus type 1.

Authors:  A D Kashuba; J R Dyer; L M Kramer; R H Raasch; J J Eron; M S Cohen
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

2.  Pharmacokinetic Interaction between amprenavir and rifabutin or rifampin in healthy males.

Authors:  R E Polk; D F Brophy; D S Israel; R Patron; B M Sadler; G E Chittick; W T Symonds; Y Lou; D Kristoff; D S Stein
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

3.  Anti-AIDS agents 90. novel C-28 modified bevirimat analogues as potent HIV maturation inhibitors.

Authors:  Keduo Qian; Ibrahim D Bori; Chin-Ho Chen; Li Huang; Kuo-Hsiung Lee
Journal:  J Med Chem       Date:  2012-09-14       Impact factor: 7.446

4.  Anterior uveitis associated with intravenous cidofovir use in patients with cytomegalovirus retinitis.

Authors:  J Ambati; K B Wynne; M C Angerame; M R Robinson
Journal:  Br J Ophthalmol       Date:  1999-10       Impact factor: 4.638

5.  Preliminary experiences with ritonavir in children with advanced HIV infection.

Authors:  G Horneff; O Adams; V Wahn
Journal:  Infection       Date:  1999 Mar-Apr       Impact factor: 3.553

Review 6.  Interactions between antiretrovirals and antineoplastic drug therapy.

Authors:  Tony Antoniou; Alice L Tseng
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

7.  Safety, pharmacokinetics, and pharmacodynamics of cyclodextrin itraconazole in pediatric patients with oropharyngeal candidiasis.

Authors:  Andreas H Groll; Lauren Wood; Maureen Roden; Diana Mickiene; Christine C Chiou; Ellen Townley; Luqman Dad; Stephen C Piscitelli; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

Review 8.  The role of protease inhibitor therapy in children with HIV infection.

Authors:  Patrick J Gavin; Ram Yogev
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

9.  Safety and effectiveness of HAART in tuberculosis-HIV co-infected patients in Brazil.

Authors:  A P G dos Santos; A G Pacheco; A Staviack; J E Golub; R E Chaisson; V C Rolla; A L Kritski; S R L Passos; F C de Queiroz Mello
Journal:  Int J Tuberc Lung Dis       Date:  2013-02       Impact factor: 2.373

10.  Anti-AIDS agents. 78. Design, synthesis, metabolic stability assessment, and antiviral evaluation of novel betulinic acid derivatives as potent anti-human immunodeficiency virus (HIV) agents.

Authors:  Keduo Qian; Donglei Yu; Chin-Ho Chen; Li Huang; Susan L Morris-Natschke; Theodore J Nitz; Karl Salzwedel; Mary Reddick; Graham P Allaway; Kuo-Hsiung Lee
Journal:  J Med Chem       Date:  2009-05-28       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.